|Articles|December 14, 2017

TFS Partners With OmniComm to Use TrialMaster® EDC

TFS International has signed a new three-year partnership agreement with OmniComm Systems, Inc. in which TFS will use OmniComm’s TrialMaster EDC technology to develop clinical studies in multiple TFS research sites around the world. Clinical trial managment along with new medicines being brought to the market are a few of the benefits to this collaboration.

Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

ByMarcela Roy, MA, Lauren Crooks, MSc, Graham Ellis, MD, Alan Kott, MUDR, Dawie Wessels, MD, Elias Ketiar, MD, MRCP

June 4th 2026

TFS Partners With OmniComm to Use TrialMaster® EDC

Related Content

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Site-First Technology Strategy, AI Data Harmonization Architecture, and Obesity Trial Retention

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention

Trending on Applied Clinical Trials Online

The Data Harmonization Imperative: How AI Is Solving Clinical Research's Biggest Bottleneck

A Shot in the Arm to Traditional Vaccine Trial Strategy

SCOPE X: How AI Could Reshape the Sponsor-Site Relationship Over the Next Several Years

ACT Brief: Cross-Asset Site Partnerships, Vaccine Trial Standardization, and Ovarian Cancer Care Gaps

Patient Engagement Strategies in Anti-Obesity Medication Clinical Trials: Addressing Drop Out Rate and Improving Retention